Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.
Frontiers In Oncology
Hintzen, Gabriele G; Dulat, Holger J HJ; Rajkovic, Erich E
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Frontiers In Oncology
Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J
Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.
Frontiers In Oncology
Mahfoudhi, Emna E; Ricordel, Charles C; Lecuyer, Gwendoline G; Mouric, Cécile C; Lena, Hervé H; Pedeux, Rémy R
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.
Cancers
Canale, Matteo M; Andrikou, Kalliopi K; Priano, Ilaria I; Cravero, Paola P; Pasini, Luigi L; Urbini, Milena M; Delmonte, Angelo A; Crinò, Lucio L; Bronte, Giuseppe G; Ulivi, Paola P
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report.
Respiratory Medicine Case Reports
Chang, Yuan Y; Liu, Shuang S; Jiang, Yanwen Y; Hua, Li L; Wen, Linfang L
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.
Nature Communications
Gong, Ke K; Guo, Gao G; Beckley, Nicole A NA; Yang, Xiaoyao X; Zhang, Yue Y; Gerber, David E DE; Minna, John D JD; Burma, Sandeep S; Zhao, Dawen D; Akbay, Esra A EA; Habib, Amyn A AA
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.
Nature Communications
Gong, Ke K; Guo, Gao G; Beckley, Nicole A NA; Yang, Xiaoyao X; Zhang, Yue Y; Gerber, David E DE; Minna, John D JD; Burma, Sandeep S; Zhao, Dawen D; Akbay, Esra A EA; Habib, Amyn A AA
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Angewandte Chemie (International Ed. In English)
Jang, Jaebong J; To, Ciric C; De Clercq, Dries J H DJH; Park, Eunyoung E; Ponthier, Charles M CM; Shin, Bo Hee BH; Mushajiang, Mierzhati M; Nowak, Radosław P RP; Fischer, Eric S ES; Eck, Michael J MJ; Jänne, Pasi A PA; Gray, Nathanael S NS